Voyager Therapeutics, Inc. - VYGR STOCK NEWS

Voyager Therapeutics (Nasdaq: VYGR) has announced an employment agreement for a new hire, which includes grants of stock options and restricted stock units. The stock option allows the purchase of 54,000 shares at an exercise price of $5.57, vesting over four years. Additionally, 27,000 restricted stock units will vest annually over three years starting January 1, 2023. These equity awards aim to attract talent essential for Voyager's advancements in gene therapy and neurology. The company's TRACER platform aims to enhance gene therapy delivery targeting neurological diseases.

Voyager Therapeutics reported third quarter 2022 results, highlighting a significant validation of its TRACERTM capsid platform after Pfizer exercised its licensing option for a novel capsid, resulting in a $10 million payment. Collaboration revenue surged to $41.1 million, compared to $1.5 million in Q3 2021. Net income stood at $17.6 million, reversing a loss from the previous year. R&D expenses increased to $19.3 million, while G&A costs decreased. Voyager expects to maintain sufficient cash flow through 2024, supported by collaboration agreements.

Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced it will disclose its third-quarter 2022 financial and operational results before the market opens on November 8, 2022. Following the results, a live conference call and webcast will occur at 8:30 a.m. ET to discuss the findings. Interested participants can register for the call to receive dial-in details and access a live webcast on Voyager's investor website. Voyager is focused on next-generation AAV gene therapy, aiming to treat debilitating diseases using its proprietary capsids from the TRACER™ discovery platform.

Voyager Therapeutics (Nasdaq: VYGR) recently announced an employment agreement with a new hire, which includes inducement awards approved by its Compensation Committee. The agreement comprises a non-qualified stock option for 60,000 shares and restricted stock units for 30,000 shares. The stock option has a ten-year term with an exercise price of $6.01 per share and vests over four years. The restricted stock units will vest annually over three years, starting on the first anniversary of the effective date, which is set for January 1, 2023.

Voyager Therapeutics (Nasdaq: VYGR) presented significant findings at the European Society of Gene & Cell Therapy (ESGCT) Congress 2022. The data revealed a novel cell surface receptor that enhances the delivery of Voyager's TRACER AAV capsids across the blood-brain barrier (BBB), showing potential for human translation. Additionally, preclinical results indicate ultra-low dosing might achieve therapeutic effects with reduced toxicity. These advancements could transform CNS drug delivery, underscoring Voyager's commitment to addressing critical neurological disorders.

Voyager Therapeutics announced that Pfizer has exercised an option to license a novel capsid from its TRACER platform, triggering a $10 million payment. This validation could lead to further potential payments totaling up to $290 million, including development and regulatory milestones. The licensed capsid targets a rare neurologic disease and supports Voyager's strategy to enhance its internal pipeline, which includes candidates for Parkinson's and ALS. This collaboration indicates strong progress and potential in the gene therapy sector.

Voyager Therapeutics (Nasdaq: VYGR) will present three posters at the 29th Annual Congress of the European Society of Gene & Cell Therapy from October 11-14, 2022, in Edinburgh, Scotland. The presentations focus on advancements in AAV gene therapy, including an engineered BBB-penetrant capsid family and evaluations of dose-response and production methodologies for AAV-based therapies. These developments may enhance treatment for neurological disorders, showcasing the company's commitment to innovation in gene therapy.

Voyager Therapeutics (Nasdaq: VYGR) announced its participation in two upcoming investor conferences. The first is Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, featuring a company presentation at 3:45 p.m. ET. The second event is the Truist Securities Genetic Medicine Summit on October 20, 2022, where Voyager will participate in a CNS panel discussion (not webcast). Interested investors can access the presentation and archived webcasts on Voyager's website for 30 days following the events.

Voyager Therapeutics (Nasdaq: VYGR) announced new employment agreements with Peter Pfreundschuh and another employee, granting them non-qualified stock options and restricted stock units. The stock options consist of 200,000 shares for Pfreundschuh and 76,000 shares for the other employee, both with an exercise price of $6.18 per share. These options will vest over four years, while the restricted stock units will vest annually over three years, starting from the first anniversary of the grant effective date of September 19, 2022.